1
|
Pierre AS, Gavriel N, Guilbard M, Ogier-Denis E, Chevet E, Delom F, Igbaria A. Modulation of Protein Disulfide Isomerase Functions by Localization: The Example of the Anterior Gradient Family. Antioxid Redox Signal 2024. [PMID: 38411504 DOI: 10.1089/ars.2024.0561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/28/2024]
Abstract
Significance: Oxidative folding within the endoplasmic reticulum (ER) introduces disulfide bonds into nascent polypeptides, ensuring proteins' stability and proper functioning. Consequently, this process is critical for maintaining proteome integrity and overall health. The productive folding of thousands of secretory proteins requires stringent quality control measures, such as the unfolded protein response (UPR) and ER-Associated Degradation (ERAD), which contribute significantly to maintaining ER homeostasis. ER-localized protein disulfide isomerases (PDIs) play an essential role in each of these processes, thereby contributing to various aspects of ER homeostasis, including maintaining redox balance, proper protein folding, and signaling from the ER to the nucleus. Recent Advances: Over the years, there have been increasing reports of the (re)localization of PDI family members and other ER-localized proteins to various compartments. A prime example is the anterior gradient (AGR) family of PDI proteins, which have been reported to relocate to the cytosol or the extracellular environment, acquiring gain of functions that intersect with various cellular signaling pathways. Critical Issues: Here, we summarize the functions of PDIs and their gain or loss of functions in non-ER locations. We will focus on the activity, localization, and function of the AGR proteins: AGR1, AGR2, and AGR3. Future Directions: Targeting PDIs in general and AGRs in particular is a promising strategy in different human diseases. Thus, there is a need for innovative strategies and tools aimed at targeting PDIs; those strategies should integrate the specific localization and newly acquired functions of these PDIs rather than solely focusing on their canonical roles.
Collapse
Affiliation(s)
- Arvin S Pierre
- INSERM U1242, University of Rennes, Rennes, France
- Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France
| | - Noa Gavriel
- Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
| | - Marianne Guilbard
- ARTiSt Group, Univ. Bordeaux, INSERM U1312, Institut Bergonié, Bordeaux, France
- Thabor Therapeutics, Paris, France
| | - Eric Ogier-Denis
- INSERM U1242, University of Rennes, Rennes, France
- Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France
| | - Eric Chevet
- INSERM U1242, University of Rennes, Rennes, France
- Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France
| | - Frederic Delom
- ARTiSt Group, Univ. Bordeaux, INSERM U1312, Institut Bergonié, Bordeaux, France
| | - Aeid Igbaria
- Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
| |
Collapse
|
2
|
Fessart D, Delom F. [Organoids in cancer research]. Bull Cancer 2024; 111:235-236. [PMID: 37872015 DOI: 10.1016/j.bulcan.2023.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Accepted: 10/01/2023] [Indexed: 10/25/2023]
Affiliation(s)
- Delphine Fessart
- ARTiSt Lab, Université de Bordeaux, Inserm U1312, 33000 Bordeaux, France
| | - Frederic Delom
- ARTiSt Lab, Université de Bordeaux, Inserm U1312, 33000 Bordeaux, France.
| |
Collapse
|
3
|
Pernot S, Tomé M, Galeano-Otero I, Evrard S, Badiola I, Delom F, Fessart D, Smani T, Siegfried G, Villoutreix BO, Khatib AM. Sulconazole inhibits PD-1 expression in immune cells and cancer cells malignant phenotype through NF-κB and calcium activity repression. Front Immunol 2024; 14:1278630. [PMID: 38250065 PMCID: PMC10796450 DOI: 10.3389/fimmu.2023.1278630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Accepted: 11/30/2023] [Indexed: 01/23/2024] Open
Abstract
The overexpression of the immunoinhibitory receptor programmed death-1 (PD1) on T-cells is involved in immune evasion in cancer. The use of anti-PD-1/PDL-1 strategy has deeply changed the therapies of cancers and patient survival. However, their efficacy diverges greatly along with tumor type and patient populations. Thereby, novel treatments are needed to interfere with the anti-tumoral immune responses and propose an adjunct therapy. In the current study, we found that the antifungal drug Sulconazole (SCZ) inhibits PD-1 expression on activated PBMCs and T cells at the RNA and protein levels. SCZ repressed NF-κB and calcium signaling, both, involved in the induction of PD-1. Further analysis revealed cancer cells treatment with SCZ inhibited their proliferation, and migration and ability to mediate tumor growth in zebrafish embryos. SCZ found also to inhibit calcium mobilization in cancer cells. These results suggest the SCZ therapeutic potential used alone or as adjunct strategy to prevent T-cell exhaustion and promotes cancer cell malignant phenotype repression in order to improve tumor eradication.
Collapse
Affiliation(s)
- Simon Pernot
- Reprograming tumor activitY and associaTed MicroenvironmEnt (Rytme), Bordeaux Institute of Oncology (BRIC)-UMR1312 Inserm, Université of Bordeaux, Pessac, France
- Institut Bergonié, Bordeaux, France
| | - Mercedes Tomé
- Reprograming tumor activitY and associaTed MicroenvironmEnt (Rytme), Bordeaux Institute of Oncology (BRIC)-UMR1312 Inserm, Université of Bordeaux, Pessac, France
| | - Isabel Galeano-Otero
- Reprograming tumor activitY and associaTed MicroenvironmEnt (Rytme), Bordeaux Institute of Oncology (BRIC)-UMR1312 Inserm, Université of Bordeaux, Pessac, France
| | - Serge Evrard
- Reprograming tumor activitY and associaTed MicroenvironmEnt (Rytme), Bordeaux Institute of Oncology (BRIC)-UMR1312 Inserm, Université of Bordeaux, Pessac, France
- Institut Bergonié, Bordeaux, France
| | - Iker Badiola
- Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain
| | - Frederic Delom
- Reprograming tumor activitY and associaTed MicroenvironmEnt (Rytme), Bordeaux Institute of Oncology (BRIC)-UMR1312 Inserm, Université of Bordeaux, Pessac, France
- Institut Bergonié, Bordeaux, France
| | - Delphine Fessart
- Reprograming tumor activitY and associaTed MicroenvironmEnt (Rytme), Bordeaux Institute of Oncology (BRIC)-UMR1312 Inserm, Université of Bordeaux, Pessac, France
- Institut Bergonié, Bordeaux, France
| | - Tarik Smani
- Group of Cardiovascular Pathophysiology, Institute of Biomedicine of Seville, University Hospital of Virgen del Rocío/University of Seville/CSIC, Seville, Spain
| | - Geraldine Siegfried
- Reprograming tumor activitY and associaTed MicroenvironmEnt (Rytme), Bordeaux Institute of Oncology (BRIC)-UMR1312 Inserm, Université of Bordeaux, Pessac, France
- Institut Bergonié, Bordeaux, France
| | - Bruno O. Villoutreix
- Integrative Computational Pharmacology and Data Mining, INSERM UMR 1141, Rob-ert-Debré Hospital, Paris, France
| | - Abdel-Majid Khatib
- Reprograming tumor activitY and associaTed MicroenvironmEnt (Rytme), Bordeaux Institute of Oncology (BRIC)-UMR1312 Inserm, Université of Bordeaux, Pessac, France
- Institut Bergonié, Bordeaux, France
| |
Collapse
|
4
|
Murray A, Gough G, Cindrić A, Vučković F, Koschut D, Borelli V, Petrović DJ, Bekavac A, Plećaš A, Hribljan V, Brunmeir R, Jurić J, Pučić-Baković M, Slana A, Deriš H, Frkatović A, Groet J, O'Brien NL, Chen HY, Yeap YJ, Delom F, Havlicek S, Gammon L, Hamburg S, Startin C, D'Souza H, Mitrečić D, Kero M, Odak L, Krušlin B, Krsnik Ž, Kostović I, Foo JN, Loh YH, Dunn NR, de la Luna S, Spector T, Barišić I, Thomas MSC, Strydom A, Franceschi C, Lauc G, Krištić J, Alić I, Nižetić D. Dose imbalance of DYRK1A kinase causes systemic progeroid status in Down syndrome by increasing the un-repaired DNA damage and reducing LaminB1 levels. EBioMedicine 2023; 94:104692. [PMID: 37451904 PMCID: PMC10435767 DOI: 10.1016/j.ebiom.2023.104692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 06/15/2023] [Accepted: 06/20/2023] [Indexed: 07/18/2023] Open
Abstract
BACKGROUND People with Down syndrome (DS) show clinical signs of accelerated ageing. Causative mechanisms remain unknown and hypotheses range from the (essentially untreatable) amplified-chromosomal-instability explanation, to potential actions of individual supernumerary chromosome-21 genes. The latter explanation could open a route to therapeutic amelioration if the specific over-acting genes could be identified and their action toned-down. METHODS Biological age was estimated through patterns of sugar molecules attached to plasma immunoglobulin-G (IgG-glycans, an established "biological-ageing-clock") in n = 246 individuals with DS from three European populations, clinically characterised for the presence of co-morbidities, and compared to n = 256 age-, sex- and demography-matched healthy controls. Isogenic human induced pluripotent stem cell (hiPSCs) models of full and partial trisomy-21 with CRISPR-Cas9 gene editing and two kinase inhibitors were studied prior and after differentiation to cerebral organoids. FINDINGS Biological age in adults with DS is (on average) 18.4-19.1 years older than in chronological-age-matched controls independent of co-morbidities, and this shift remains constant throughout lifespan. Changes are detectable from early childhood, and do not require a supernumerary chromosome, but are seen in segmental duplication of only 31 genes, along with increased DNA damage and decreased levels of LaminB1 in nucleated blood cells. We demonstrate that these cell-autonomous phenotypes can be gene-dose-modelled and pharmacologically corrected in hiPSCs and derived cerebral organoids. Using isogenic hiPSC models we show that chromosome-21 gene DYRK1A overdose is sufficient and necessary to cause excess unrepaired DNA damage. INTERPRETATION Explanation of hitherto observed accelerated ageing in DS as a developmental progeroid syndrome driven by DYRK1A overdose provides a target for early pharmacological preventative intervention strategies. FUNDING Main funding came from the "Research Cooperability" Program of the Croatian Science Foundation funded by the European Union from the European Social Fund under the Operational Programme Efficient Human Resources 2014-2020, Project PZS-2019-02-4277, and the Wellcome Trust Grants 098330/Z/12/Z and 217199/Z/19/Z (UK). All other funding is described in details in the "Acknowledgements".
Collapse
Affiliation(s)
- Aoife Murray
- Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK; The London Down Syndrome Consortium (LonDownS), London, UK.
| | - Gillian Gough
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
| | - Ana Cindrić
- Glycoscience Research Laboratory, Genos Ltd., Zagreb, Croatia
| | - Frano Vučković
- Glycoscience Research Laboratory, Genos Ltd., Zagreb, Croatia
| | - David Koschut
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Disease Intervention Technology Laboratory (DITL), Institute of Molecular and Cellular Biology (IMCB), Agency for Science, Technology and Research (A∗STAR), Singapore
| | - Vincenzo Borelli
- Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy
| | - Dražen J Petrović
- Glycoscience Research Laboratory, Genos Ltd., Zagreb, Croatia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Ana Bekavac
- Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Ante Plećaš
- Faculty of Veterinary Medicine, Department of Anatomy, Histology and Embryology, University of Zagreb, Zagreb, Croatia
| | - Valentina Hribljan
- Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Reinhard Brunmeir
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
| | - Julija Jurić
- Glycoscience Research Laboratory, Genos Ltd., Zagreb, Croatia
| | | | - Anita Slana
- Glycoscience Research Laboratory, Genos Ltd., Zagreb, Croatia
| | - Helena Deriš
- Glycoscience Research Laboratory, Genos Ltd., Zagreb, Croatia
| | - Azra Frkatović
- Glycoscience Research Laboratory, Genos Ltd., Zagreb, Croatia
| | - Jűrgen Groet
- Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK; The London Down Syndrome Consortium (LonDownS), London, UK
| | - Niamh L O'Brien
- Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK; The London Down Syndrome Consortium (LonDownS), London, UK
| | - Hong Yu Chen
- Institute of Molecular and Cell Biology (IMCB), A∗STAR, Singapore
| | - Yee Jie Yeap
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
| | - Frederic Delom
- Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK
| | - Steven Havlicek
- Laboratory of Neurogenetics, Genome Institute of Singapore, A∗STAR, Singapore
| | - Luke Gammon
- Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK
| | - Sarah Hamburg
- The London Down Syndrome Consortium (LonDownS), London, UK
| | - Carla Startin
- The London Down Syndrome Consortium (LonDownS), London, UK; Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Division of Psychiatry, University College London, London, UK; School of Psychology, University of Roehampton, London, UK
| | - Hana D'Souza
- The London Down Syndrome Consortium (LonDownS), London, UK; Centre for Brain and Cognitive Development, Birkbeck, University of London, London, UK
| | - Dinko Mitrečić
- Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Mijana Kero
- Department of Medical Genetics, Children's Hospital Zagreb, Centre of Excellence for Reproductive and Regenerative Medicine, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Ljubica Odak
- Department of Medical Genetics, Children's Hospital Zagreb, Centre of Excellence for Reproductive and Regenerative Medicine, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Božo Krušlin
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Željka Krsnik
- Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Ivica Kostović
- Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Jia Nee Foo
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Laboratory of Neurogenetics, Genome Institute of Singapore, A∗STAR, Singapore
| | - Yuin-Han Loh
- Institute of Molecular and Cell Biology (IMCB), A∗STAR, Singapore
| | - Norris Ray Dunn
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Institute of Molecular and Cell Biology (IMCB), A∗STAR, Singapore
| | - Susana de la Luna
- ICREA, Genome Biology Programme (CRG), Universitat Pompeu Fabra (UPF), CIBER of Rare Diseases, Barcelona, Spain
| | - Tim Spector
- Department of Twin Research and Genetic Epidemiology, King's College London, London, UK
| | - Ingeborg Barišić
- Department of Medical Genetics, Children's Hospital Zagreb, Centre of Excellence for Reproductive and Regenerative Medicine, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Michael S C Thomas
- The London Down Syndrome Consortium (LonDownS), London, UK; Centre for Brain and Cognitive Development, Birkbeck, University of London, London, UK
| | - Andre Strydom
- The London Down Syndrome Consortium (LonDownS), London, UK; Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Division of Psychiatry, University College London, London, UK
| | - Claudio Franceschi
- Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy; Institute of Information Technologies, Mathematics and Mechanics, Lobachevsky State University, Nizhny Novgorod 603022, Russia
| | - Gordan Lauc
- Glycoscience Research Laboratory, Genos Ltd., Zagreb, Croatia; Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
| | | | - Ivan Alić
- Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK; Faculty of Veterinary Medicine, Department of Anatomy, Histology and Embryology, University of Zagreb, Zagreb, Croatia.
| | - Dean Nižetić
- Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK; The London Down Syndrome Consortium (LonDownS), London, UK; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
| |
Collapse
|
5
|
Chevet E, Bassal F, Beq S, Bonhomme B, Boisteau E, Calloch J, Cazals-Hatem D, Delom F, Fessart D, Evrard S, Hrstka R, Hupp T, Lièvre A, Louis E, Mariau J, Meuwis MA, Ogier-Denis E, Paradis V, Pernot S, Pineau R, Treton X, Velasco V, Vieujean S. AGR2 protein expression in colorectal tumour epithelialcompartment. Gut 2022; 72:gutjnl-2022-328739. [PMID: 36591613 PMCID: PMC10715535 DOI: 10.1136/gutjnl-2022-328739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Accepted: 11/01/2022] [Indexed: 01/03/2023]
Affiliation(s)
- Eric Chevet
- U1242, INSERM, Rennes, France
- Centre de Lutte Contre le Cancer Eugene Marquis, Rennes, France
- University of Rennes, Rennes, France
| | - F Bassal
- Thabor Therapeutics, Paris, France
| | | | | | - Emeric Boisteau
- U1242, INSERM, Rennes, France
- Department of Gastroenterology, CHU Rennes, Rennes, France
| | | | - Dominique Cazals-Hatem
- Gastroenterology, IBD and intestinal failure department, Beaujon Hospital, Clichy, France
| | - Frederic Delom
- Bordeaux II University, Talence, France
- U1312, INSERM, Bordeaux, France
| | - Delphine Fessart
- Bordeaux II University, Talence, France
- U1312, INSERM, Bordeaux, France
| | - Serge Evrard
- Institut Bergonié, Bordeaux, France
- Bordeaux II University, Talence, France
| | - Roman Hrstka
- Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - Ted Hupp
- University of Edinbhurg, Edinburgh, UK
| | - Astrid Lièvre
- Department of Gastroenterology, CHU Rennes, Rennes, France
| | - Edouard Louis
- Hepato-gastroenterology and digestive oncology, University Hospital CHU of Liège and laboratory of translational gastroenterology, GIGA institute, ULiège, Liège, Belgium
| | | | - Marie-Alice Meuwis
- Hepato-gastroenterology and digestive oncology, University Hospital CHU of Liège and laboratory of translational gastroenterology, GIGA institute, ULiège, Liège, Belgium
| | - Eric Ogier-Denis
- U1242, INSERM, Rennes, France
- Centre de Lutte Contre le Cancer Eugene Marquis, Rennes, France
- University of Rennes, Rennes, France
| | - Valerie Paradis
- Pathology, Assistance Publique-Hôpitaux de Paris (AP-HP), Clichy, France
| | | | - R Pineau
- U1242, INSERM, Rennes, France
- Centre de Lutte Contre le Cancer Eugene Marquis, Rennes, France
- University of Rennes, Rennes, France
| | - Xavier Treton
- Gastroenterology Department, Hôpital Beaujon, MICI et Assistance Nutritive, APHP, Paris, France
| | | | - Sophie Vieujean
- Hepato-gastroenterology and digestive oncology, University Hospital CHU of Liège and laboratory of translational gastroenterology, GIGA institute, ULiège, Liège, Belgium
| |
Collapse
|
6
|
Abstract
The AGR2 and AGR3 genes have been shown by numerous groups to be functionally associated with adenocarcinoma progression and metastasis. In this paper, we explore the data available in databases concerning genomic and transcriptomic features of these two genes: the NCBI dbSNP database was used to explore the presence and roles of constitutional SNPs, and the NCI, Cancer Cell Line Encyclopedia (CCLE) and TCGA databases were used to explore somatic mutations and copy number variations (CNVs), as well as mRNA expression of these genes in human cancer cell lines and tumours. Relationships of AGR2/3 expression with whole-genome mRNA expression and cancer features (i.e. mutations and CNVs of oncogenes and tumour suppressor genes (TSG)) were established using the CCLE and TCGA databases. In addition, the CCLE data concerning CRISPR gene extinction screens (Achilles project) of these two genes and a panel of oncogenes and TSG were explored. We observed that no functional polymorphism or recurrent mutation could be detected in AGR2 or AGR3. The expression of these genes was positively correlated with the expression of epithelial genes and inversely correlated with that of mesenchymal genes. It was also significantly associated with several cancer features, such as TP53 or SMAD4 mutations, depending on the gene and the cancer type. In addition, the CRISPR screens revealed the absence of cell fitness modification upon gene extinction, in contrast with oncogenes (cell fitness decrease) and TSG (cell fitness increase). Overall, these explorations revealed that AGR2 and AGR3 proteins appear as common non-genetic evolutionary factors in the process of human tumorigenesis.
Collapse
Affiliation(s)
- Delphine Fessart
- ARTiSt, University Bordeaux, INSERM U1312, Bordeaux F-33000, France,POETIC, University Bordeaux, INSERM U1312, Bordeaux F-33000, France
| | - Ines Villamor
- POETIC, University Bordeaux, INSERM U1312, Bordeaux F-33000, France
| | - Eric Chevet
- INSERM U1242, ‘Chemistry, Oncogenesis Stress Signaling’, Université Rennes 1, Rennes, France,Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France
| | - Frederic Delom
- ARTiSt, University Bordeaux, INSERM U1312, Bordeaux F-33000, France
| | - Jacques Robert
- ARTiSt, University Bordeaux, INSERM U1312, Bordeaux F-33000, France
| |
Collapse
|
7
|
Delom F, Le Morvan V, Robert J, Fessart D. [Normal organoids and their applications in cancer research]. Bull Cancer 2021; 109:58-64. [PMID: 34903368 DOI: 10.1016/j.bulcan.2021.11.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Revised: 11/04/2021] [Accepted: 11/12/2021] [Indexed: 11/18/2022]
Abstract
Three-dimensional (3D) culture of organoids from primary cells (wild type) or tumoroids from tumor cells, is used to study the physiological mechanisms in vivo, in order to model normal or tumor tissues more accurately than conventional two-dimensional (2D) culture. The features of this 3D culture, such as the three-dimensional structure, the self-renewal capacity and differentiation are preserved and appropriate to cancer study since their cellular characteristics are very similar to in vivo models. Here, we summarize the recent advances in the rapidly evolving field of organoids and their applications to cancer biology, clinical research and personalized medicine.
Collapse
Affiliation(s)
- Frederic Delom
- ARTiSt group, Univ Bordeaux, Inserm, Institut Bergonié, ACTION, U1218, 33000 Bordeaux, France
| | - Valérie Le Morvan
- ARTiSt group, Univ Bordeaux, Inserm, Institut Bergonié, ACTION, U1218, 33000 Bordeaux, France
| | - Jacques Robert
- ARTiSt group, Univ Bordeaux, Inserm, Institut Bergonié, ACTION, U1218, 33000 Bordeaux, France
| | - Delphine Fessart
- ARTiSt group, Univ Bordeaux, Inserm, Institut Bergonié, ACTION, U1218, 33000 Bordeaux, France; Inserm U1242, "chemistry, oncogenesis stress signaling", université Rennes 1, 35000 Rennes, France; Centre de lutte contre le cancer Eugène Marquis, 35000 Rennes, France.
| |
Collapse
|
8
|
Fessart D, Robert J, Hartog C, Chevet E, Delom F, Babin G. The Anterior GRadient (AGR) family proteins in epithelial ovarian cancer. J Exp Clin Cancer Res 2021; 40:271. [PMID: 34452625 PMCID: PMC8394676 DOI: 10.1186/s13046-021-02060-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Accepted: 08/04/2021] [Indexed: 01/29/2023] Open
Abstract
Epithelial ovarian cancer (EOC) is the most common gynecologic disorder. Even with the recent progresses made towards the use of new therapeutics, it still represents the most lethal gynecologic malignancy in women from developed countries. The discovery of the anterior gradient proteins AGR2 and AGR3, which are highly related members belonging to the protein disulfide isomerase (PDI) family, attracted researchers’ attention due to their putative involvement in adenocarcinoma development. This review compiles the current knowledge on the role of the AGR family and the expression of its members in EOC and discusses the potential clinical relevance of AGR2 and AGR3 for EOC diagnosis, prognosis, and therapeutics. A better understanding of the role of the AGR family may thus provide new handling avenues for EOC patients.
Collapse
Affiliation(s)
- Delphine Fessart
- INSERM U1242, "Chemistry, Oncogenesis Stress Signaling", Université Rennes 1, Rennes, France. .,Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France. .,ARTiSt group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000, Bordeaux, France.
| | - Jacques Robert
- ARTiSt group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000, Bordeaux, France
| | - Cecile Hartog
- ARTiSt group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000, Bordeaux, France
| | - Eric Chevet
- INSERM U1242, "Chemistry, Oncogenesis Stress Signaling", Université Rennes 1, Rennes, France.,Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France
| | - Frederic Delom
- ARTiSt group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000, Bordeaux, France.
| | - Guillaume Babin
- ARTiSt group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000, Bordeaux, France.
| |
Collapse
|
9
|
Fessart D, de Barbeyrac C, Boutin I, Grenier T, Richard E, Begueret H, Bernard D, Chevet E, Robert J, Delom F. Extracellular AGR2 triggers lung tumour cell proliferation through repression of p21 CIP1. Biochim Biophys Acta Mol Cell Res 2020; 1868:118920. [PMID: 33278424 DOI: 10.1016/j.bbamcr.2020.118920] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Revised: 10/12/2020] [Accepted: 11/05/2020] [Indexed: 01/05/2023]
Abstract
The human Anterior GRadient 2 (AGR2) protein is an Endoplasmic Reticulum (ER)-resident protein which belongs to the Protein-Disulfide Isomerase (PDI) superfamily and is involved to productive protein folding in the ER. As such AGR2, often found overexpressed in adenocarcinomas, contributes to tumour development by enhancing ER proteostasis. We previously demonstrated that AGR2 is secreted (extracellular AGR2 (eAGR2)) in the tumour microenvironment and plays extracellular roles independent of its ER functions. Herein, we show that eAGR2 triggers cell proliferation and characterize the underlying molecular mechanisms. We demonstrate that eAGR2 enhances tumour cell growth by repressing the tumour suppressor p21CIP1. Our findings shed light on a novel mechanism through which eAGR2 behaves as a growth factor in the tumour microenvironment, independently of its ER function, thus promoting tumour cell growth through repression of p21CIP1. Our results provide a rationale for targeting eAGR2/p21CIP1-based signalling as a potential therapeutic target to impede tumour growth.
Collapse
Affiliation(s)
- Delphine Fessart
- ARTiSt Group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000 Bordeaux, France; INSERM U1242, "Chemistry, Oncogenesis Stress Signaling", Univ. Rennes, Rennes, France; Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France.
| | - Claire de Barbeyrac
- ARTiSt Group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000 Bordeaux, France
| | - Ines Boutin
- ARTiSt Group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000 Bordeaux, France
| | - Thomas Grenier
- ARTiSt Group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000 Bordeaux, France
| | - Elodie Richard
- ARTiSt Group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000 Bordeaux, France
| | - Hughes Begueret
- ARTiSt Group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000 Bordeaux, France; Dept of Pathology, University Hospital of Bordeaux, Hopital Haut-Lévêque, Pessac, France
| | - David Bernard
- Inserm U1052, CNRS UMR 5286, Université de Lyon & Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Eric Chevet
- INSERM U1242, "Chemistry, Oncogenesis Stress Signaling", Univ. Rennes, Rennes, France; Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France
| | - Jacques Robert
- ARTiSt Group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000 Bordeaux, France
| | - Frederic Delom
- ARTiSt Group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000 Bordeaux, France.
| |
Collapse
|
10
|
Delom F, Begiristain I, Grenier T, Begueret H, Soulet F, Siegfried G, Khatib AM, Robert J, Fessart D. Patients Lung Derived Tumoroids (PLDTs) to model therapeutic response. Biochim Biophys Acta Mol Cell Res 2020; 1867:118808. [PMID: 32781095 DOI: 10.1016/j.bbamcr.2020.118808] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Revised: 07/29/2020] [Accepted: 07/30/2020] [Indexed: 11/25/2022]
Abstract
Preclinical lung cancer models are essential for a basic understanding of lung cancer biology and its translation into efficient treatment options for affected patients. Lung cancer cell lines and xenografts derived directly from human lung tumors have proven highly valuable in fundamental oncology research and anticancer drug discovery. Both models inherently comprise advantages and caveats that have to be accounted for. Recently, we have enabled reliable in vitro culture techniques from lung cancer biopsies as Patients Lung Derived Tumoroids (PLDTs). This breakthrough provides the possibility of high-throughput drug screening covering the spectrum of lung cancer phenotypes seen clinically. We have adapted and optimized our in vitro three-dimensional model as a preclinical lung cancer model to recapitulate the tumor microenvironment (TME) using matrix reconstitution. Hence, we developed directly PLDTs to screen for chemotherapeutics and radiation treatment. This original model will enable precision medicine to become a reality, allowing a given patient sample to be screened for effective ex vivo therapeutics, aiming at tailoring of treatments specific to that individual. Hence, this tool can enhance clinical outcomes and avoid morbidity due to ineffective therapies.
Collapse
Affiliation(s)
- Frederic Delom
- ARTiSt Group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000 Bordeaux, France.
| | - Inaki Begiristain
- ARTiSt Group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000 Bordeaux, France
| | - Thomas Grenier
- ARTiSt Group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000 Bordeaux, France
| | - Hugues Begueret
- ARTiSt Group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000 Bordeaux, France; Hôpital Haut-Lévêque, CHU de Bordeaux, avenue de Magellan, 33604 Pessac cedex, France
| | - Fabienne Soulet
- Université de Bordeaux, Bordeaux, France; INSERM UMR1029, 33400, Pessac, France
| | - Geraldine Siegfried
- Université de Bordeaux, Bordeaux, France; INSERM UMR1029, 33400, Pessac, France
| | - Abdel-Majid Khatib
- Université de Bordeaux, Bordeaux, France; INSERM UMR1029, 33400, Pessac, France
| | - Jacques Robert
- ARTiSt Group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000 Bordeaux, France
| | - Delphine Fessart
- INSERM U1242, "Chemistry, Oncogenesis Stress Signaling", Univ. Rennes 1, F-35000 Rennes, France; Centre de Lutte Contre le Cancer Eugène Marquis, F-35000 Rennes, France; ARTiSt Group, Univ. Bordeaux, INSERM, Institut Bergonié, ACTION, U1218, F-33000 Bordeaux, France.
| |
Collapse
|
11
|
Abstract
The anterior gradient-2 (AGR2) is an endoplasmic reticulum (ER)-resident protein belonging to the protein disulfide isomerase family that mediates the formation of disulfide bonds and assists the protein quality control in the ER. In addition to its role in proteostasis, extracellular AGR2 is responsible for various cellular effects in many types of cancer, including cell proliferation, survival, and metastasis. Various OMICs approaches have been used to identify AGR2 binding partners and to investigate the functions of AGR2 in the ER and outside the cell. Emerging data showed that AGR2 exists not only as monomer, but it can also form homodimeric structure and thus interact with different partners, yielding different biological outcomes. In this review, we summarize the AGR2 “interactome” and discuss the pathological and physiological role of such AGR2 interactions.
Collapse
Affiliation(s)
- Frederic Delom
- University of Bordeaux, ACTION, Bordeaux, France
- Institut National de la Santé et de la Recherche Médicale, Bordeaux, France
- Institut Bergonié, Bordeaux, France
| | - M. Aiman Mohtar
- University Kebangsaan Malaysia, Medical Molecular Biology Institute (UMBI), The National University of Malaysia, Kuala Lumpur, Malaysia
| | - Ted Hupp
- University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, Scotland, United Kingdom
- University of Gdansk, International Centre for Cancer Vaccine Science, Gdansk, Poland
| | - Delphine Fessart
- University of Bordeaux, ACTION, Bordeaux, France
- Institut National de la Santé et de la Recherche Médicale, Bordeaux, France
- Institut Bergonié, Bordeaux, France
| |
Collapse
|
12
|
Obacz J, Sommerova L, Sicari D, Durech M, Avril T, Iuliano F, Pastorekova S, Hrstka R, Chevet E, Delom F, Fessart D. Extracellular AGR3 regulates breast cancer cells migration via Src signaling. Oncol Lett 2019; 18:4449-4456. [PMID: 31611954 PMCID: PMC6781763 DOI: 10.3892/ol.2019.10849] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Accepted: 06/25/2019] [Indexed: 12/18/2022] Open
Abstract
Human anterior gradient proteins AGR2 and AGR3 are overexpressed in a variety of adenocarcinomas and are often secreted in cancer patients' specimens, which suggests a role for AGR proteins in intra and extracellular compartments. Although these proteins exhibit high sequence homology, AGR2 is predominantly described as a pro-oncogene and a potential prognostic biomarker. However, little is known about the function of AGR3. Therefore, the aim of the present study was to investigate the role of AGR3 in breast cancer. The results demonstrated that breast cancer cells secrete AGR3. Furthermore, it was revealed that extracellular AGR3 (eAGR3) regulates tumor cell adhesion and migration. The current study indicated that the pharmacological and genetic perturbation of Src kinase signaling, through treatment with Dasatinib (protein kinase inhibitor) or investigating cells that express a dominant-negative form of Src, significantly abrogated eAGR3-mediated breast cancer cell migration. Therefore, the results indicated that eAGR3 may control tumor cell migration via activation of Src kinases. The results of the present study indicated that eAGR3 may serve as a microenvironmental signaling molecule in tumor-associated processes.
Collapse
Affiliation(s)
- Joanna Obacz
- INSERM U1242, 'Chemistry, Oncogenesis Stress Signaling', University of Rennes Campus 1, F-35000 Rennes, France.,Centre de Lutte Contre le Cancer Eugène Marquis, F-35000 Rennes, France.,Masaryk Memorial Cancer Institute, RECAMO, 656 53 Brno, Czech Republic.,Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovak Republic
| | - Lucia Sommerova
- Masaryk Memorial Cancer Institute, RECAMO, 656 53 Brno, Czech Republic
| | - Daria Sicari
- INSERM U1242, 'Chemistry, Oncogenesis Stress Signaling', University of Rennes Campus 1, F-35000 Rennes, France
| | - Michal Durech
- Masaryk Memorial Cancer Institute, RECAMO, 656 53 Brno, Czech Republic
| | - Tony Avril
- INSERM U1242, 'Chemistry, Oncogenesis Stress Signaling', University of Rennes Campus 1, F-35000 Rennes, France.,Centre de Lutte Contre le Cancer Eugène Marquis, F-35000 Rennes, France
| | - Filippo Iuliano
- Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovak Republic
| | - Silvia Pastorekova
- Masaryk Memorial Cancer Institute, RECAMO, 656 53 Brno, Czech Republic.,Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovak Republic
| | - Roman Hrstka
- Masaryk Memorial Cancer Institute, RECAMO, 656 53 Brno, Czech Republic
| | - Eric Chevet
- INSERM U1242, 'Chemistry, Oncogenesis Stress Signaling', University of Rennes Campus 1, F-35000 Rennes, France.,Centre de Lutte Contre le Cancer Eugène Marquis, F-35000 Rennes, France
| | - Frederic Delom
- University of Bordeaux, ACTION, F-33000 Bordeaux, France.,INSERM U1218, F-33000 Bordeaux, France.,Bergonie Cancer Institute, F-33000 Bordeaux, France
| | - Delphine Fessart
- INSERM U1242, 'Chemistry, Oncogenesis Stress Signaling', University of Rennes Campus 1, F-35000 Rennes, France.,Centre de Lutte Contre le Cancer Eugène Marquis, F-35000 Rennes, France.,University of Bordeaux, ACTION, F-33000 Bordeaux, France.,INSERM U1218, F-33000 Bordeaux, France
| |
Collapse
|
13
|
Delom F, Nazaraliyev A, Fessart D. The role of protein disulphide isomerase AGR2 in the tumour niche. Biol Cell 2018; 110:271-282. [DOI: 10.1111/boc.201800024] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Revised: 08/21/2018] [Accepted: 09/06/2018] [Indexed: 12/15/2022]
Affiliation(s)
- Frederic Delom
- University of Bordeaux; INSERM U1218; Bordeaux F-33000 France
- Institut Bergonié, Comprehensive Cancer Centre; Bordeaux F-33076 France
| | - Amal Nazaraliyev
- University of Bordeaux; INSERM U1218; Bordeaux F-33000 France
- Institut Bergonié, Comprehensive Cancer Centre; Bordeaux F-33076 France
| | - Delphine Fessart
- INSERM U1242; “Chemistry, Oncogenesis, Stress, Signaling”; Université; de Rennes 1; Rennes France
- Centre de Lutte Contre le Cancer Eugène Marquis; Rennes France
| |
Collapse
|
14
|
Fessart D, Domblides C, Avril T, Eriksson LA, Begueret H, Pineau R, Malrieux C, Dugot-Senant N, Lucchesi C, Chevet E, Delom F. Secretion of protein disulphide isomerase AGR2 confers tumorigenic properties. eLife 2016; 5. [PMID: 27240165 PMCID: PMC4940162 DOI: 10.7554/elife.13887] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Accepted: 05/28/2016] [Indexed: 12/31/2022] Open
Abstract
The extracellular matrix (ECM) plays an instrumental role in determining the spatial orientation of epithelial polarity and the formation of lumens in glandular tissues during morphogenesis. Here, we show that the Endoplasmic Reticulum (ER)-resident protein anterior gradient-2 (AGR2), a soluble protein-disulfide isomerase involved in ER protein folding and quality control, is secreted and interacts with the ECM. Extracellular AGR2 (eAGR2) is a microenvironmental regulator of epithelial tissue architecture, which plays a role in the preneoplastic phenotype and contributes to epithelial tumorigenicity. Indeed, eAGR2, is secreted as a functionally active protein independently of its thioredoxin-like domain (CXXS) and of its ER-retention domain (KTEL), and is sufficient, by itself, to promote the acquisition of invasive and metastatic features. Therefore, we conclude that eAGR2 plays an extracellular role independent of its ER function and we elucidate this gain-of-function as a novel and unexpected critical ECM microenvironmental pro-oncogenic regulator of epithelial morphogenesis and tumorigenesis. DOI:http://dx.doi.org/10.7554/eLife.13887.001 Cancer cells multiply abnormally fast and therefore produce protein molecules faster than normal cells. To avoid becoming stressed by this overproduction, cancer cells make use of proteins that fold the new proteins inside the cell. One of these protein folders is called anterior gradient-2 (or AGR2 for short) and is produced at high levels in so-called epithelial cancers, such as breast and lung cancer. Previous research has shown that AGR2 inside cancer cells can help them grow and survive and AGR2 can also be found outside cells, such as in the blood or the urine of cancer patients. Therefore some researchers have suggested that measuring the levels of AGR2 in bodily fluids may be a useful marker for detecting cancers. Fessart et al. hypothesized that – apart from becoming a promising diagnostic tool – the AGR2 protein itself, specifically when found outside cells, might make cancer cells more aggressive. Fessart et al. used a range of techniques to test this hypothesis. For example, healthy lung cells and lung cancer cells were grown into miniature replicas of lung organs in the laboratory, and in a key experiment, AGR2 was added to the lung organoids grown from the healthy cells. The addition of AGR2 protein was enough to change the non-tumor organoids into tumor organoids and boosted their growth about ten-fold. Further experiments then revealed that AGR2 also makes cells more invasive and capable of moving, both important features of aggressive cancer cells. Overall, Fessart et al. have proven that AGR2 is a signalling molecule found outside cancer cells that makes them more aggressive. In future, more research addressing how AGR2 achieves this may lead to new therapeutic strategies against some forms of cancer. DOI:http://dx.doi.org/10.7554/eLife.13887.002
Collapse
Affiliation(s)
- Delphine Fessart
- Oncogenesis, Stress and Signaling Laboratory, ERL440 Inserm, Université de Rennes 1, Rennes, France.,Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France.,INSERM U1218, Actions for onCogenesis understanding and Target Identification in ONcology (ACTION), Bordeaux, France.,Bergonié Cancer Institute, Bordeaux, France
| | | | - Tony Avril
- Oncogenesis, Stress and Signaling Laboratory, ERL440 Inserm, Université de Rennes 1, Rennes, France.,Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France
| | - Leif A Eriksson
- Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden
| | | | - Raphael Pineau
- Animalerie mutualisée, Université de Bordeaux, Bordeaux, France
| | - Camille Malrieux
- INSERM U1218, Actions for onCogenesis understanding and Target Identification in ONcology (ACTION), Bordeaux, France.,Bergonié Cancer Institute, Bordeaux, France.,Université de Bordeaux, Bordeaux, France
| | | | - Carlo Lucchesi
- Bergonié Cancer Institute, Bordeaux, France.,Site de Recherche Intégrée sur le Cancer, Bordeaux Recherche Intégrée en Oncologie, Bordeaux, France
| | - Eric Chevet
- Oncogenesis, Stress and Signaling Laboratory, ERL440 Inserm, Université de Rennes 1, Rennes, France.,Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France
| | - Frederic Delom
- INSERM U1218, Actions for onCogenesis understanding and Target Identification in ONcology (ACTION), Bordeaux, France.,Bergonié Cancer Institute, Bordeaux, France.,Université de Bordeaux, Bordeaux, France
| |
Collapse
|
15
|
Delom F, Danner-Boucher I, Dromer C, Thumerel M, Marthan R, Nourry-Lecaplain L, Magnan A, Jougon J, Fessart D. Impact of donor-to-recipient weight ratio on survival after bilateral lung transplantation. Transplant Proc 2015; 46:1517-22. [PMID: 24935323 DOI: 10.1016/j.transproceed.2014.02.015] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2013] [Revised: 01/27/2014] [Accepted: 02/27/2014] [Indexed: 11/27/2022]
Abstract
BACKGROUND The aim of this study was to investigate the relationship between donor-to-recipient weight ratio and post-transplantation survival. METHODS From February 1988 to November 2006, 255 adult bilateral lung transplantation patients from 2 different centers were retrospectively analyzed. The cohort was divided into 4 groups depending on the quartile ranges of the donor-to-recipient weight ratio. A time-to-event analysis was performed for risk of death after transplantation conditional on 5-year survival using Kaplan-Meier and Cox proportional hazards models. RESULTS The mean weight ratio for the study cohort was 1.23 ± 0.39. For all lung transplant recipients during the study period, survival rate at 5 years was 58%. Median survival was 6.3 years in the cohort subgroup with weight ratio <1.23, whereas the median survival was 7.7 years for the cohort subgroup with weight ratio >1.23. Weight ratio >1.23 recipients had a significant survival advantage out to 5 years compared with weight ratio <1.23 recipients (66.1% vs 51.1%, P = .0126). With the aim to assess underweight and overweight donors vs recipients, we have divided all patients into 4 groups, from quartile 1 to 4, based on donor-to-recipient weight ratio. Weight ratio strata affected overall survival, with quartile 1 (lower weight ratio recipients) experiencing the lowest 5-year survival (39.1%), followed by quartile 2 (57.8%), quartile 4 (68.2%), and quartile 3 (70.3%) recipients. The effect of weight ratio strata on survival was statistically significant for the quartile 1 recipients (lower quartile) as compared with the 3 other quartiles. CONCLUSIONS Our findings show a statistically significant effect of donor-to-recipient weight ratios on bilateral lung transplantation survival. A higher donor-to-recipient weight ratio was associated with improved survival after bilateral lung transplantation and likely reflects a mismatch between a relatively overweight donor vs recipient. In contrast, a lower donor-to-recipient ratio was associated with increased mortality after bilateral lung transplantation.
Collapse
Affiliation(s)
- F Delom
- University of Bordeaux, Centre de recherche Cardio-Thoracique de Bordeaux, Bordeaux, France; INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, Bordeaux, France
| | - I Danner-Boucher
- Institut du thorax, DHU2020, INSERM UMR 1087, Service de pneumologie, CHU de Nantes, Université de Nantes, France
| | - C Dromer
- Department of Thoracic and Cervical Surgery and Lung Transplantation, Haut-Levêque Hospital, Pessac, France
| | - M Thumerel
- Department of Thoracic and Cervical Surgery and Lung Transplantation, Haut-Levêque Hospital, Pessac, France
| | - R Marthan
- University of Bordeaux, Centre de recherche Cardio-Thoracique de Bordeaux, Bordeaux, France; INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, Bordeaux, France
| | - L Nourry-Lecaplain
- Institut du thorax, DHU2020, INSERM UMR 1087, Service de pneumologie, CHU de Nantes, Université de Nantes, France
| | - A Magnan
- Institut du thorax, DHU2020, INSERM UMR 1087, Service de pneumologie, CHU de Nantes, Université de Nantes, France
| | - J Jougon
- Department of Thoracic and Cervical Surgery and Lung Transplantation, Haut-Levêque Hospital, Pessac, France
| | - D Fessart
- University of Bordeaux, Centre de recherche Cardio-Thoracique de Bordeaux, Bordeaux, France; INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, Bordeaux, France.
| |
Collapse
|
16
|
Fessart D, Begueret H, Delom F. Three-dimensional culture model to distinguish normal from malignant human bronchial epithelial cells. Eur Respir J 2013; 42:1345-56. [DOI: 10.1183/09031936.00118812] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
17
|
Fessart D, Dromer C, Thumerel M, Jougon J, Delom F. Influence of gender donor-recipient combinations on survival after human lung transplantation. Transplant Proc 2012; 43:3899-902. [PMID: 22172868 DOI: 10.1016/j.transproceed.2011.08.101] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2011] [Revised: 07/30/2011] [Accepted: 08/31/2011] [Indexed: 11/19/2022]
Abstract
BACKGROUND In the current practice of lung transplantation, donor and recipient genders are neither directly considered nor matched. However, some data have suggested a possible effect of gender combinations on survival following lung transplantation. METHODS A total of 249 adult lung transplant recipients at a single center between February 1988 and December 2008, were analyzed retrospectively for donor-recipient gender matching. We compared the mortality by calculating one-term survival rates after transplantation using the Kaplan-Meier method with comparisons using the log-rank (Mantel-Cox) test. Statistical significance of the mean effects of size matching was assessed by paired Student t tests and Wilcoxon signed rank tests. RESULTS Kaplan-Meier survival analysis shown that male compared to female recipients did not have an effect on outcomes after lung transplantation at 5 years (P=.5379), 10 years (P=.107), 15 years (P=.0841), 20 years (P=.0711). No effect of gender on lung transplantation outcomes was observed with donor-recipient gender mismatches at 5 years (P=.1804), 10 years (P=.1457), 15 years (P=.0731), or 20 years (P=.0629). Similarly, no differences were observed for each gender combination. The degree of size matching was defined as the ratio of donor-to-recipient predicted total lung capacity. The ratios were similar for the donor-recipient gender match and significantly different for the donor-recipient gender mismatch. CONCLUSIONS These analyses suggested that gender was not a significant independent risk factor affecting survival after lung transplantation. Size mismatch caused by gender mismatch did not increase mortality.
Collapse
Affiliation(s)
- D Fessart
- Bordeaux University, Bordeaux Cardiothoracic Research Center, Inserm U1045, Bordeaux, France
| | | | | | | | | |
Collapse
|
18
|
De Vita S, Canzonetta C, Mulligan C, Delom F, Groet J, Baldo C, Vanes L, Dagna-Bricarelli F, Hoischen A, Veltman J, Fisher EMC, Tybulewicz VLJ, Nizetic D. Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome. Oncogene 2010; 29:6102-14. [PMID: 20697343 PMCID: PMC3007620 DOI: 10.1038/onc.2010.351] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Children with Down's syndrome (DS) have 20–50-fold higher incidence of all leukaemias (lymphoid and myeloid), for reasons not understood. As incidence of many solid tumours is much lower in DS, we speculated that disturbed early haematopoietic differentiation could be the cause of increased leukaemia risk. If a common mechanism is behind the risk of both major leukaemia types, it would have to arise before the bifurcation to myeloid and lymphoid lineages. Using the transchromosomic system (mouse embryonic stem cells (ESCs)) bearing an extra human chromosome 21 (HSA21)) we analyzed the early stages of haematopoietic commitment (mesodermal colony formation) in vitro. We observed that trisomy 21 (T21) causes increased production of haemogenic endothelial cells, haematopoietic stem cell precursors and increased colony forming potential, with significantly increased immature progenitors. Transchromosomic colonies showed increased expression of Gata-2, c-Kit and Tie-2. A panel of partial T21 ESCs allowed us to assign these effects to HSA21 sub-regions, mapped by 3.5 kbp-resolution tiling arrays. The Gata-2 increase on one side, and c-Kit and Tie-2 increases on the other, could be attributed to two different, non-overlapping HSA21 regions. Using human-specific small interfering RNA silencing, we could demonstrate that an extra copy of RUNX1, but not ETS-2 or ERG, causes an increase in Tie-2/c-Kit levels. Finally, we detected significantly increased levels of RUNX1, C-KIT and PU.1 in human foetal livers with T21. We conclude that overdose of more than one HSA21 gene contributes to the disturbance of early haematopoiesis in DS, and that one of the contributors is RUNX1. As the observed T21-driven hyperproduction of multipotential immature precursors precedes the bifurcation to lymphoid and myeloid lineages, we speculate that this could create conditions of increased chance for acquisition of pre-leukaemogenic rearrangements/mutations in both lymphoid and myeloid lineages during foetal haematopoiesis, contributing to the increased risk of both leukaemia types in DS.
Collapse
Affiliation(s)
- S De Vita
- Queen Mary University of London, Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, Centre for Paediatrics, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Wang Y, Mulligan C, Denyer G, Delom F, Dagna-Bricarelli F, Tybulewicz VLJ, Fisher EMC, Griffiths WJ, Nizetic D, Groet J. Quantitative proteomics characterization of a mouse embryonic stem cell model of Down syndrome. Mol Cell Proteomics 2009; 8:585-95. [PMID: 19001410 PMCID: PMC2667343 DOI: 10.1074/mcp.m800256-mcp200] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2008] [Revised: 10/30/2008] [Indexed: 11/06/2022] Open
Abstract
Down syndrome, caused by the trisomy of chromosome 21, is a complex condition characterized by a number of phenotypic features, including reduced neuron number and synaptic plasticity, early Alzheimer disease-like neurodegeneration, craniofacial dysmorphia, heart development defects, increased incidence of childhood leukemia, and powerful suppression of the incidence of most solid tumors. Mouse models replicate a number of these phenotypes. The Tc1 Down syndrome model was constructed by introducing a single supernumerary human chromosome 21 into a mouse embryonic stem cell, and it reproduces a large number of Down syndrome phenotypes including heart development defects. However, little is still known about the developmental onset of the trisomy 21-induced mechanisms behind these phenotypes or the proteins that are responsible for them. This study determined the proteomic differences that are present in undifferentiated embryonic stem cells and are caused by an additional human chromosome 21. A total of 1661 proteins were identified using two-dimensional liquid chromatography followed by tandem mass spectrometry from whole embryonic stem cell lysates. Using isobaric tags for relative and absolute quantification, we found 52 proteins that differed in expression by greater than two standard deviations from the mean when an extra human chromosome 21 was present. Of these, at least 11 have a possible functional association with a Down syndrome phenotype or a human chromosome 21-encoded gene. This study also showed that quantitative protein expression differences in embryonic stem cells can persist to adult mouse as well as reproduce in human Down syndrome fetal tissue. This indicates that changes that are determined in embryonic stem cells of Down syndrome could potentially identify proteins that are involved in phenotypes of Down syndrome, and it shows that these cell lines can be used for the purpose of studying these pathomechanisms.
Collapse
Affiliation(s)
- Yuqin Wang
- Institute of Mass-Spectrometry, School of Medicine, Swansea University, Singleton Park, Swansea SA2 8PP, United Kingdom
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Canzonetta C, Mulligan C, Deutsch S, Ruf S, O'Doherty A, Lyle R, Borel C, Lin-Marq N, Delom F, Groet J, Schnappauf F, De Vita S, Averill S, Priestley JV, Martin JE, Shipley J, Denyer G, Epstein CJ, Fillat C, Estivill X, Tybulewicz VL, Fisher EM, Antonarakis SE, Nizetic D. DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. Am J Hum Genet 2008; 83:388-400. [PMID: 18771760 PMCID: PMC2556438 DOI: 10.1016/j.ajhg.2008.08.012] [Citation(s) in RCA: 117] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2008] [Revised: 07/10/2008] [Accepted: 08/20/2008] [Indexed: 10/21/2022] Open
Abstract
Down syndrome (DS) is the most common cause of mental retardation. Many neural phenotypes are shared between DS individuals and DS mouse models; however, the common underlying molecular pathogenetic mechanisms remain unclear. Using a transchromosomic model of DS, we show that a 30%-60% reduced expression of Nrsf/Rest (a key regulator of pluripotency and neuronal differentiation) is an alteration that persists in trisomy 21 from undifferentiated embryonic stem (ES) cells to adult brain and is reproducible across several DS models. Using partially trisomic ES cells, we map this effect to a three-gene segment of HSA21, containing DYRK1A. We independently identify the same locus as the most significant eQTL controlling REST expression in the human genome. We show that specifically silencing the third copy of DYRK1A rescues Rest levels, and we demonstrate altered Rest expression in response to inhibition of DYRK1A expression or kinase activity, and in a transgenic Dyrk1A mouse. We reveal that undifferentiated trisomy 21 ES cells show DYRK1A-dose-sensitive reductions in levels of some pluripotency regulators, causing premature expression of transcription factors driving early endodermal and mesodermal differentiation, partially overlapping recently reported downstream effects of Rest +/-. They produce embryoid bodies with elevated levels of the primitive endoderm progenitor marker Gata4 and a strongly reduced neuroectodermal progenitor compartment. Our results suggest that DYRK1A-mediated deregulation of REST is a very early pathological consequence of trisomy 21 with potential to disturb the development of all embryonic lineages, warranting closer research into its contribution to DS pathology and new rationales for therapeutic approaches.
Collapse
Affiliation(s)
- Claudia Canzonetta
- Institute of Cell and Molecular Science, Barts & The London, Queen Mary's School of Medicine and Dentistry, University of London, 4 Newark Street, London E1 2AT, UK
| | - Claire Mulligan
- Institute of Cell and Molecular Science, Barts & The London, Queen Mary's School of Medicine and Dentistry, University of London, 4 Newark Street, London E1 2AT, UK
| | - Samuel Deutsch
- Department of Genetic Medicine and Development, Geneva University Medical School, Geneva CH-1211, Switzerland
| | - Sandra Ruf
- National Institute for Medical Research, Mill Hill, London NW7 1AA, UK
| | - Aideen O'Doherty
- National Institute for Medical Research, Mill Hill, London NW7 1AA, UK
- Department of Neurodegenerative Disease, Institute of Neurology, University College London, London WC1N 3BG, UK
| | - Robert Lyle
- Department of Genetic Medicine and Development, Geneva University Medical School, Geneva CH-1211, Switzerland
| | - Christelle Borel
- Department of Genetic Medicine and Development, Geneva University Medical School, Geneva CH-1211, Switzerland
| | - Nathalie Lin-Marq
- Department of Genetic Medicine and Development, Geneva University Medical School, Geneva CH-1211, Switzerland
| | - Frederic Delom
- Institute of Cell and Molecular Science, Barts & The London, Queen Mary's School of Medicine and Dentistry, University of London, 4 Newark Street, London E1 2AT, UK
| | - Jürgen Groet
- Institute of Cell and Molecular Science, Barts & The London, Queen Mary's School of Medicine and Dentistry, University of London, 4 Newark Street, London E1 2AT, UK
| | - Felix Schnappauf
- Institute of Cell and Molecular Science, Barts & The London, Queen Mary's School of Medicine and Dentistry, University of London, 4 Newark Street, London E1 2AT, UK
| | - Serena De Vita
- Institute of Cell and Molecular Science, Barts & The London, Queen Mary's School of Medicine and Dentistry, University of London, 4 Newark Street, London E1 2AT, UK
| | - Sharon Averill
- Institute of Cell and Molecular Science, Barts & The London, Queen Mary's School of Medicine and Dentistry, University of London, 4 Newark Street, London E1 2AT, UK
| | - John V. Priestley
- Institute of Cell and Molecular Science, Barts & The London, Queen Mary's School of Medicine and Dentistry, University of London, 4 Newark Street, London E1 2AT, UK
| | - Joanne E. Martin
- Institute of Cell and Molecular Science, Barts & The London, Queen Mary's School of Medicine and Dentistry, University of London, 4 Newark Street, London E1 2AT, UK
| | - Janet Shipley
- The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
| | - Gareth Denyer
- Department of Biochemistry, University of Sydney, Sydney NSW 2006, Australia
| | - Charles J. Epstein
- Department of Pediatrics, University of California, San Francisco, CA 94143-2911, USA
| | - Cristina Fillat
- Genes and Disease Program, Center for Genomic Regulation (CRG-UPF), and CIBERESP and CIBERER, Barcelona 08003, Spain
| | - Xavier Estivill
- Genes and Disease Program, Center for Genomic Regulation (CRG-UPF), and CIBERESP and CIBERER, Barcelona 08003, Spain
| | | | - Elizabeth M.C. Fisher
- Department of Neurodegenerative Disease, Institute of Neurology, University College London, London WC1N 3BG, UK
| | - Stylianos E. Antonarakis
- Department of Genetic Medicine and Development, Geneva University Medical School, Geneva CH-1211, Switzerland
| | - Dean Nizetic
- Institute of Cell and Molecular Science, Barts & The London, Queen Mary's School of Medicine and Dentistry, University of London, 4 Newark Street, London E1 2AT, UK
| |
Collapse
|
21
|
Delom F, Emadali A, Cocolakis E, Lebrun JJ, Nantel A, Chevet E. Calnexin-dependent regulation of tunicamycin-induced apoptosis in breast carcinoma MCF-7 cells. Cell Death Differ 2006; 14:586-96. [PMID: 16858427 DOI: 10.1038/sj.cdd.4402012] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
The endoplasmic reticulum (ER) has evolved specific mechanisms to ensure protein folding as well as the maintenance of its own homeostasis. When these functions are not achieved, specific ER stress signals are triggered to activate either adaptive or apoptotic responses. Here, we demonstrate that MCF-7 cells are resistant to tunicamycin-induced apoptosis. We show that the expression level of the ER chaperone calnexin can directly influence tunicamycin sensitivity in this cell line. Interestingly, the expression of a calnexin lacking the chaperone domain (DeltaE) partially restores their sensitivity to tunicamycin-induced apoptosis. Indeed, we show that DeltaE acts as a scaffold molecule to allow the cleavage of Bap31 and thus generate the proapoptotic p20 fragment. Utilizing the ability of MCF-7 cells to resist tunicamycin-induced apoptosis, we have characterized a molecular mechanism by which calnexin regulates ER-stress-mediated apoptosis in a manner independent of its chaperone functions but dependent of its binding to Bap31.
Collapse
Affiliation(s)
- F Delom
- Department of Surgery, McGill University, Montreal, Quebec, Canada
| | | | | | | | | | | |
Collapse
|
22
|
Siffroi-Fernandez S, Delom F, Nlend MC, Lanet J, Franc JL, Giraud A. Identification of thyroglobulin domain(s) involved in cell-surface binding and endocytosis. J Endocrinol 2001; 170:217-26. [PMID: 11431154 DOI: 10.1677/joe.0.1700217] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Thyroglobulin (Tg) binds to cell surfaces through various binding sites of high, moderate and low affinity. We have previously shown that binding with low to moderate affinity is pH dependent, selective, but not tissue specific. To identify the regions of Tg involved in this cell surface binding, we studied the binding of (125)I-labeled cyanogen bromide peptides from human Tg to cell surfaces of thyroid cells (inside-out follicles) and of CHO cells. Electrophoretic analysis of cell homogenates after binding of native or of reduced and alkylated (125)I-labeled peptides showed that three peptides, P1, P2 and P3, were always associated with the cells. Sequence analysis allowed the identification of P1 (Ser-2445 to Met-2596 or Met-2610) and P2 (Phe-2156 to Met-2306). P3 proved to be a mixture of several peptides among which two were identified: P3-1 (Cys-1306 to Met-1640) and P3-2 (Cys-2035 to Met-2413) which includes P2. P1, P2 and P3-2 are entirely (P1) or partly (P2 and P3-2) located in the C-terminal domain of Tg homologous with acetylcholinesterase. The smallest peptides, P1 and P2, were purified by preparative electrophoresis. They both displayed strong binding properties towards cell surfaces. Inhibition experiments of (125)I-labeled Tg binding by P1 or P2 indicated that they were involved in Tg binding to cell surfaces. All the other peptides tested for their binding abilities were either not or only poorly involved in Tg binding to cell surfaces, which suggested that P1 and P2 are major Tg sites of binding to cell surfaces. These two peptides are not involved in the binding of Tg to the known Tg 'receptors' described in the literature, to which recycling, transcytosis and regulation functions have been ascribed. Thus they are potential tools to identify cell surface components involved in the process of Tg endocytosis leading to lysosomal degradation.
Collapse
Affiliation(s)
- S Siffroi-Fernandez
- INSERM U-555 and Laboratoire de Biochimie Endocrinienne et Métabolique, Faculté de Médecine, Université de la Mediterranée, Marseille, France
| | | | | | | | | | | |
Collapse
|
23
|
Delom F, Mallet B, Carayon P, Lejeune PJ. Role of extracellular molecular chaperones in the folding of oxidized proteins. Refolding of colloidal thyroglobulin by protein disulfide isomerase and immunoglobulin heavy chain-binding protein. J Biol Chem 2001; 276:21337-42. [PMID: 11294872 DOI: 10.1074/jbc.m101086200] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The process of thyroid hormone synthesis, which occurs in the lumen of the thyroid follicles, results from an oxidative reaction leading, as side effects, to the multimerization of thyroglobulin (TG), the prothyroid hormone. Although hormone synthesis is a continuous process, the amount of Tg multimers is relatively constant. Here, we investigated the role of two molecular chaperones, protein disulfide isomerase (PDI) and immunoglobulin heavy chain-binding protein (BiP), present in the follicular lumen, on the multimerization process due to oxidation using both native Tg and its N-terminal domain (NTD). In vitro, PDI decreased multimerization of Tg and even suppressed the formation of NTD multimers. Under the same conditions, BiP was able to bind to Tg and NTD multimers but did not affect the process of multimerization. Associating BiP with PDI did not enhance the ability of PDI to limit the formation of multimers produced by oxidation. However, when BiP and PDI were reacted together with the multimeric forms and for a longer time (48 h), BiP greatly increased the efficiency of PDI. Accordingly, these two molecular chaperones probably act sequentially on the reduction of the intermolecular disulfide bridges. In the thyroid, a similar process may also be effective and participate in limiting the amount of Tg multimers present in the colloid. These results suggest that extracellular molecular chaperones play a similar role to that occurring in the endoplasmic reticulum and, furthermore, take part in the control of multimerization and aggregation of proteins formed by oxidation.
Collapse
Affiliation(s)
- F Delom
- Unité 555 INSERM and Laboratoire de Biochimie Endocrinienne et Métabolique, Faculté de Médecine, Université de la Méditerranée, 13385 Marseille Cedex 5, France
| | | | | | | |
Collapse
|
24
|
Duthoit C, Estienne V, Delom F, Durand-Gorde JM, Mallet B, Carayon P, Ruf J. Production of immunoreactive thyroglobulin C-terminal fragments during thyroid hormone synthesis. Endocrinology 2000; 141:2518-25. [PMID: 10875253 DOI: 10.1210/endo.141.7.7573] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Here, we studied the fragmentation of the prothyroid hormone, thyroglobulin (Tg), which occurs during thyroid hormone synthesis, a process which involves iodide, thyroperoxidase, and the H2O2-generating system, consisting of glucose and glucose oxidase. Various peptides were found to be immunoreactive to autoantibodies to Tg from patients and monoclonal antibodies directed against the immunodominant region of Tg. The smallest peptide (40 kDa) bore thyroid hormones and was identified at the C-terminal end of the Tg molecule, which shows homologies with acetylcholinesterase. Similar peptides were obtained by performing metal-mediated oxidation of Tg via a Fenton reaction. It was concluded that the oxidative stress induced during hormone synthesis generates free radicals, which, in turn, cleave Tg into immunoreactive peptides.
Collapse
Affiliation(s)
- C Duthoit
- Unit 38 of the French Institute of Health and Medical Research, Faculté de Médecine Timone, Université de la Méditerranée, Marseille
| | | | | | | | | | | | | |
Collapse
|
25
|
Delom F, Lejeune PJ, Vinet L, Carayon P, Mallet B. Involvement of oxidative reactions and extracellular protein chaperones in the rescue of misassembled thyroglobulin in the follicular lumen. Biochem Biophys Res Commun 1999; 255:438-43. [PMID: 10049727 DOI: 10.1006/bbrc.1999.0229] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Reactive oxygen species (ROS) are involved in many pathological processes through modifications of structure and activity of proteins. ROS also participate in physiological pathways such as thyroid hormone biosynthesis, which proceeds through oxidation of the prothyroid hormone (thyroglobulin, Tg) and iodide. Regarding the colloidal insoluble multimerized Tg (m-Tg), which bears dityrosine bridges and is present in the follicular lumen, a mild oxidative system generated different soluble forms of Tg, more or less compacted by hydrophobic associations, and linked with Grp78 and Grp94. In vitro, the combined action of ROS and PDI, in the presence of free glutathione (reduced/oxidized), increased the solubility of this misassembled Tg and partially restored the ability of Tg to synthesize hormones. Our results show that protein chaperones escape from the ER and are involved with ROS in thyroid hormone synthesis. Therefore, we propose a model of roles of m-Tg in the follicular lumen.
Collapse
Affiliation(s)
- F Delom
- Unité 38 INSERM, Faculté de Médecine, Marseille, France
| | | | | | | | | |
Collapse
|
26
|
Abstract
Thyroglobulin (Tg), the prothyroid hormone, is stored in the lumen of the thyroid follicles as soluble dimers and tetramers and insoluble multimers, Soluble Tg is well characterized with regards to structure and role, but insoluble Tg (i-Tg) is not. Here we show that i-Tg, multimerized through formation of disulfide and dityrosine bonds, has a higher iodine content than soluble Tg and no thyroid hormones. Furthermore, the size and the resistance of i-Tg to proteolytic enzymes implied a new mechanism by which thyrocytes may degrade this form of Tg. Using peroxidase and H2O2 generating system, we found that about 80% of i-Tg was degraded and 24% of its iodine content was released. Our data point to a role for i-Tg in iodine storage and the involvement of TPO in i-Tg degradation and iodide release.
Collapse
Affiliation(s)
- N Baudry
- Faculté de Médecine, Unité 38 INSERM, Marseille, France
| | | | | | | | | | | |
Collapse
|